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Regulatory T cells suppress autoimmune responses to self-antigens. Recent studies, 
including one in this issue of Cell (Wu et al., 2006), suggest that the ability of T cells to 
choose between launching a productive immune response, functional inactivation, or 
developing into regulatory T cells depends upon the interplay of the key transcriptional 
regulators FOXP3 and NFAT.The immune system of higher organisms is faced with 
the daily challenge of distinguishing between foreign and 
“self” antigens. Part of this challenge involves recognizing 
the molecular features of the environment that an organ-
ism is chronically exposed to (such as products of com-
mensal flora) in addition to its own molecular components. 
Furthermore, this “self” antigenic landscape evolves dur-
ing the life span of an organism because of the expres-
sion of temporally regulated genes (e.g., during metamor-
phosis or sexual maturation) and of a changing microbial 
and nonmicrobial environment. Thus, it is a daunting task 
to evolve a regulatory mechanism that allows the immune 
system to efficiently protect against infection while avoid-
ing destruction of the organism by lymphocytes bearing 
receptors specific for self-antigens. Avoiding self-reactivity 
is particularly challenging for T cells whose antigen recep-
tors (TCRs) recognize short peptides bound to MHC gene 
products. T cells recognize peptide-MHC complexes on 
antigen-presenting cells that are generated during continu-
ous turnover of endogenously synthesized and internalized 
proteins. The overwhelming majority of MHC bound pep-
tides are derived from self proteins because the antigen-
processing machinery and MHC molecules themselves do 
not discriminate between self or foreign protein products. 
To make matters even more complicated, certain low-avid-
ity interactions of TCRs with self-peptide-MHC complexes 
are necessary for the successful maturation of T cells in the 
thymus and for their survival in the periphery.
One obstacle to the spurious activation of naive periph-
eral T cells upon TCR recognition of self-ligands is a 
requirement for an additional signal. This signal emanates 
from a costimulatory activating receptor, such as CD28, 
for a productive immune response to proceed. The cos-
timulatory molecules CD80 and CD86 serve as CD28 lig-
ands and are upregulated in antigen-presenting cells upon 
exposure to microbial products that are recognized by a 
set of evolutionarily conserved pattern recognition recep-
tors (Janeway, 1989; Medzhitov and Janeway, 1999). The 
immunological self/non-self-discrimination based on the 
two-signal requirement is complemented by mechanisms 
of immunological tolerance operating in a cell-intrinsic (recessive) and cell-extrinsic (dominant) fashion (described 
below). In this issue of Cell, Wu et al. (2006) suggest a con-
nection between the transcriptional mechanisms that facil-
itate recessive and dominant tolerance.
Recessive Tolerance: Clonal Deletion and Anergy
During their development in the thymus, the majority of 
thymocytes with TCRs that exhibit high avidity for self-
peptide-MHC complexes undergo programmed cell 
death resulting in the deletion of autoreactive clones. 
Those high-affinity self-reactive thymocytes that escape 
deletion acquire a state of unresponsiveness to TCR stim-
ulation known as anergy. These mechanisms constitute 
recessive T cell tolerance. Recessive tolerance can also 
be induced after mature thymocytes exit the thymus as 
peripheral T cells subjected to chronic TCR stimulation 
by high-affinity ligands undergo deletion or become aner-
gic. Recent studies revealed that the induction of anergy 
is an active process, and, at least in mature peripheral T 
cells, anergy can be elicited by sustained Ca+2 signaling 
caused by TCR induction. Ca+2signaling leads to activa-
tion of members of the NFAT family of transcription fac-
tors in the absence of their interacting partner AP-1 (the 
Fos-Jun heterodimer) (Macian et al., 2002). In peripheral 
T cells, AP-1 is induced by CD28-mediated signals, and 
productive immune responses are dependent upon the 
cooperative binding of the NFAT/AP-1 transcriptional com-
plex to the corresponding sequence elements within the 
promoter regions of certain genes. These genes encode 
factors involved in the immune response including IL-2, 
a major T cell growth factor, and IL-2 receptor α chain 
(CD25). In contrast, a distinct transcriptional program of 
anergy executed by NFAT in the absence of AP-1 leads to 
inability of T cells to mount a proliferative response to TCR 
engagement, to produce IL-2, as well as to differentiate 
into effector cells producing cytokines such as IFN-γ or 
TNF-α. Instead, anergized T cells express increased lev-
els of IL-10, a potent anti-inflammatory cytokine. The aner-
gic state in T cells is characterized by a sharp increase in 
the threshold of TCR activation and is actively maintained 
by continuous TCR stimulation. Providing exogenous IL-2 Cell 126, July 28, 2006 ©2006 Elsevier Inc. 253
and strong TCR/CD28 stimulation can break anergy and 
result in productive activation of anergic T cells. In this 
regard, anergy induction in a very broad sense can be 
considered as a special case of cell-intrinsic negative 
feedback regulation.
Dominant Tolerance Mediated by Regulatory T 
Cells: A Key Role for FOXP3
The aforementioned recessive tolerance mechanisms 
are complemented by a mechanism of dominant (cell-
extrinsic) regulation of overexuberant immune responses 
mediated by a specialized subset of suppressive CD4 T 
lymphocytes. These cells, euphemistically dubbed regu-
latory T (Treg) cells, keep in check self-reactive T cells by 
poorly understood suppressive mechanisms. Treg cells, 
initially characterized by high level of surface expression 
of CD25, normally develop in the thymus and constitute 
?7%–15% of peripheral CD4 T cells. Treg cells appear to 
exhibit some characteristic features of anergy as they fail 
to efficiently flux Ca+2, proliferate on their own, or produce 
IL-2 as well as proinflammatory cytokines in response to 
TCR stimulation (see for review Sakaguchi, 2005).
Recently, the X chromosome-encoded transcription 
factor FOXP3 was shown to be expressed exclusively in 
Treg cells and required for their development in the thy-
mus (see for review Ramsdell, 2003; Fontenot and Ruden-
sky, 2005). Furthermore, in peripheral T cells, forced 
expression of a Foxp3 transgene resulted in acquisition 
of suppressive function. FOXP3 was originally cloned 
as a gene mutated in patients with IPEX (immune dys-
regulation, polyendocrinopathy, entheropathy, X-linked) 
syndrome and in the spontaneous mouse mutant scurfy. 
In IPEX patients, multiple mutations in the FOXP3 DNA 
binding forkhead domain (FKH) and leucine zipper have 
been reported (see for review Ramsdell, 2003; Ochs et 
al., 2005). Both in humans and mice, Foxp3 mutations 
result in fatal aggressive autoimmune pathology affect-
ing multiple organs. Importantly, an identical pheno-
type was observed in mice in which a conditional Foxp3 
allele was ablated specifically in the germline and the T 
cell lineage. This result suggests that a Foxp3 lesion in T 
cells is entirely responsible for the pathology associated 
with FOXP3 deficiency (Fontenot et al., 2005b). The lat-
ter observation—combined with the lack of a detectable 
role for Foxp3 in recessive tolerance or in the regulation of 
proliferative response and cytokine production by periph-
eral T cells—showed that the breakdown of dominant tol-
erance, i.e., lack of the Treg cells, results in early-onset, 
highly aggressive fatal autoimmunity. Thus, FOXP3 is a 
principal and dedicated mediator of the genetic mecha-
nism of dominant tolerance (Fontenot et al., 2005b).
Transcriptional profiling of Treg cells expressing FOXP3 
in comparison to naive or activated T cells revealed a sub-
stantial number of differentially expressed genes. Rela-
tively few mRNAs are downregulated whereas expression 
of the majority of genes is increased. The latter group 
includes some of the genes normally upregulated in acti-
vated T cells, such as Il2ra (CD25), Ctla4 (CTLA-4), and 254 Cell 126, July 28, 2006 ©2006 Elsevier Inc.Tnfrsf18 (GITR). In agreement with the functional data, the 
IL-2 message was repressed in Treg cells when compared 
to activated T cells (see for review Sakaguchi, 2005; Fon-
tenot and Rudensky, 2005). Although the FOXP3-depend-
ent genetic program has remained largely unknown, Il2ra 
and Il2 have become prototype target genes for FOXP3. 
Indeed, it was shown recently that FOXP3-mediated 
repression of NFAT-dependent transcription occurs upon 
FOXP3 binding to a consensus forkhead binding motif 
that overlaps with the AP-1 site within the NFAT/AP-1 
binding DNA-regulatory element. Thus, it was proposed 
that FOXP3 may compete with NFAT/AP-1 complexes 
for Il2 regulatory elements (Ziegler, 2006). These early 
experiments were corroborated and further extended by 
FOXP3 overexpression studies using retroviral transduc-
tion of activated T cells (Bettelli et al., 2005; Grant et al., 
2006). The latter experiments also suggested that FOXP3 
might also repress NF-κB and CREB transcriptional tar-
gets in activated T cells. Transient and stable transfec-
tion studies indicated that in addition to DNA binding FKH 
domain, FOXP3 protein-protein interaction domains, a 
unique proline-rich N-terminal region, and a leucine-zip-
per dimerization domain are required for FOXP3 function 
(Ziegler, 2006; Wu et al., 2006). A substantial caveat to 
these studies is that FOXP3 was overexpressed in cells 
that may lack FOXP3 cofactors or regulating signals. 
However, these results are consistent with the biochemi-
cal and structural analyses of the binding of other FOXP 
family members to DNA, which revealed a somewhat 
low affinity for DNA, suggesting a need for dimerization 
and interacting partners to facilitate FOXP transcriptional 
activity (Li et al., 2004; Stroud et al., 2006).
A Mechanistic Link between Transcriptional 
Control of Recessive and Dominant Tolerance
These observations raised a question of a possible role 
for NFAT not only in facilitating recessive tolerance via its 
role in anergy induction but also in dominant tolerance 
via its cooperation with FOXP3. Wu et al. (2006) now 
produce experimental evidence in support of this possi-
bility by demonstrating cooperative binding of NFAT and 
FOXP3 to DNA. By solving the structure of NFAT and the 
related FOXP2 FKH domain bound to DNA, this study 
also provides details of the molecular interactions in this 
ternary complex (Wu et al., 2006). The latter experiments 
led to realization that structural requirements for NFAT 
interaction with AP-1 and FKH domain transcription fac-
tors are distinct, providing potential means to manipu-
late these interactions in the future using site-specific 
chemical inhibitors. More importantly, based on the 
structure, the authors mutated residues in the predicted 
NFAT interaction sites within the FOXP3 FKH domain 
to create a compound WWRR FOXP3 mutant (T359W 
N361W E399R E401R). This mutant lacks the ability to 
repress Il2 transcription upon retroviral transduction 
of activated T cells. Moreover, T cells transduced with 
the WWRR FOXP3 mutant—compared to T cells trans-
duced with wild-type FOXP3—showed a lower increase 
Figure 1. NFAT Transcriptional Complexes 
in T Cell Activation
(Left panel) Activation of the NFAT/AP-1 tran-
scriptional complex by TCR (T cell receptor) 
activation and CD28 stimulation induces a pro-
ductive immune response resulting in cytokine 
production and effector T cell differentiation. 
(Middle panel) TCR stimulation in the absence 
of costimulatory signals results in NFAT, but 
not AP-1, activation and anergy. (Right panel) 
FOXP3 expression in response to an unknown 
signal diverts T cells from “anergic” cell fate, and 
NFAT/FOXP3 transcriptional complexes facili-
tate regulatory T cell differentiation.in the expression of CD25 and GITR. This result sug-
gests that NFAT:FOXP3 cooperatively bind to the regu-
latory elements of genes (such as those encoding CD25 
and GITR) that have an altered expression in Treg cells. 
Indeed, in T cells transduced with FOXP3—and in Treg 
cells propagated in vitro in the presence of IL-2—both 
NFAT and FOXP3 seem to bind within the promoter 
regions of genes that encode IL-2, CTLA-4, and CD25 
as illustrated by chromatin immunoprecipitation experi-
ments (Wu et al., 2006). How do NFAT:FOXP3 complexes 
impart negative and positive regulation upon binding to 
the corresponding regulatory elements within the same 
cell? Further in-depth analysis of the molecular makeup 
of higher-order transcriptional complexes formed by 
FOXP3 in Treg cells will address this issue. Another 
intriguing observation in these experiments was that 
FOXP3 and NFAT binding to the promoters of the genes 
that encode CTLA-4, IL-2, and CD25 was detected upon 
stimulation of transduced or ex vivo isolated T cells by 
PMA and ionomycin or ionomycin alone, respectively. At 
face value, these results suggest that Ca+2 signaling is 
required to detect NFAT and FOXP3 binding to the afore-
mentioned promoters. If these data can be extrapolated 
to regulation of gene expression in Treg cells in vivo, Ca+2 
signaling-dependent regulation of the occupancy of the 
corresponding promoters by NFAT along with FOXP3 in 
activated versus resting Treg cell states may not translate 
into significant changes in expression of these genes at 
the protein level. This is because resting Treg cells have 
a uniformly high level of CD25 expression. It remains to 
be seen whether chronic TCR stimulation that Treg cells 
typically encounter is sufficient to sustain occupancy of 
regulatory regions of NFAT:FOXP3 target genes in vivo.
Biochemical studies by Wu and coauthors suggest 
that the genes that encode CTLA-4, CD25, and IL-2 
serve as direct targets of an NFAT:FOXP3 complex in 
Treg cells. However, arguably one of the most intriguing 
questions was raised by the final set of functional experi-
ments in which T cells specific for pancreatic antigens 
were transduced with the WWRR FOXP3 mutant. These 
transduced cells failed to acquire suppressive func-
tion and failed to prevent the development of diabetes 
caused by the adoptive cotransfer of untransduced pan-
creatic antigen-specific T cells. In contrast, T cell trans-
duced with wild-type FOXP3 protein conferred potent 
suppressive capacity (Wu et al., 2006). These data imply that NFAT:FOXP3 mediated regulation of a still myste-
rious mechanism of Treg-mediated suppression or of 
differentiation of Treg cells. It seems unlikely that high-
level CD25 expression in Treg cells is directly involved in 
regulation of their suppressive function or differentiation 
as CD25-deficient Treg cells develop and are capable 
of suppression at least in vitro (Fontenot et al., 2005a). 
A potential role for CTLA-4 in mediating suppression 
remains controversial as the arguments exist both for 
and against a role for CTLA-4 as a nonredundant sup-
pressive molecule (reviewed in Sakaguchi, 2005). Addi-
tionally, a biological significance of FOXP3-mediated 
repression of IL-2 gene expression in Treg cells and its 
relevance to their suppressive function are unclear. This 
leaves open a possibility of a yet unknown molecular 
mechanism of Treg development or suppressive func-
tion dependent upon NFAT:FOXP3 cooperation. Obvi-
ously, this argument depends upon a very specific effect 
of WWRR mutations, i.e., exclusive impairment of NFAT:
FOXP3 cooperative binding, but not NFAT-independent 
binding to DNA either in partnership with other tran-
scriptional regulators or in a cofactor-independent man-
ner. Identification of NFAT-dependent and -independent 
transcriptional programs mediated by FOXP3 in Treg 
cells will be instrumental in clarifying these issues.
Models for Regulatory T Cell Development
The emerging model of a lineage choice between effec-
tor versus regulatory T cell differentiation determined 
upon NFAT partnership with AP-1 or FOXP3, with anergy 
resulting from failure of both differentiation pathways (i.e., 
AP-1 and FOXP3 induction), is appealing in its simplic-
ity (see Figure 1; Wu et al., 2006). This model is likely 
applicable to the generation of Treg cells in the periph-
ery in response to chronic exposure to suboptimal TCR 
stimulation as recently demonstrated for TCR transgenic 
T cells exposed to low amounts of the cognate ligand in 
vivo (Kretschmer et al., 2005). In addition to TCR trigger-
ing, recent in vitro studies suggested a role for high dose 
of TGF-β in FOXP3 induction in peripheral T cells (Figure 
2; reviewed in Sakaguchi, 2005). However, the aforemen-
tioned scenario may be more complex if a CD28 signal is 
required for peripheral Treg generation (see below). As an 
additional note of caution, it is far from certain whether 
differentiation of peripheral polyclonal T cells specific for 
self or foreign antigens into FOXP3-expressing Treg cells Cell 126, July 28, 2006 ©2006 Elsevier Inc. 255
Figure 2. differentiation of Regulatory T 
Cells expressing FOXP3 in the Thymus 
and in the Periphery
The thymus represents the main site for regula-
tory T cell differentiation. FOXP3 expression in 
the thymus is dependent upon TCR, CD28, and 
γc-cytokine receptor signaling and perhaps an 
additional yet unknown factor(s). (Inset) In the 
periphery, chronic suboptimal TCR stimulation 
is capable of inducing FOXP3 expression in na-
ive T cells. TGF-β receptor signaling might also 
contribute to acquisition of FOXP3 expression in 
peripheral T cells in vivo.contributes in a substantial way to the overall peripheral 
Treg cell population and whether this process is essential 
for the maintenance of immune homeostasis under physi-
ologic condition or during infection.
In contrast, a critical role for thymic differentiation 
of Treg cells is strongly suggested by the autoimmu-
nity typically observed in day 3 thymectomized mice 
(Sakaguchi, 2005). More recently, comparative analysis 
of TCR repertoires displayed by thymic and peripheral 
Treg cells indicated substantial similarity between these 
Treg subsets as opposed to the relatively small over-
lap between TCR repertoires displayed by thymic and 
peripheral nonregulatory T cells (Hsieh et al., 2006). Fur-
thermore, recent analysis of Leishmania-specific Treg 
cells present in skin of infected mice revealed that none 
of these cells acquired FOXP3 expression upon encoun-
ter with the pathogen. Instead, essentially all these cells 
originate from pre-existing Treg cell population (Suffia 
et al., 2006). In agreement with the day 3 thymectomy 
studies, these results suggest that thymically generated 
FOXP3-expressing Treg cells predominantly contribute 
to functional Treg population in the periphery with some 
possible exceptions for specific microenvironments 
such as the tumor microenvironment.
Can the model of NFAT:FOXP3-dependent generation 
of Treg cells in the periphery be extended to the thymus? 
Consistent with the model, regulatory T cells develop-
ing in the thymus use TCR with an increased affinity for 
self-peptide-MHC complexes (normally subjected to 
anergy induction) and this signal seems to be necessary 
for induction of FOXP3 expression (reviewed in Saka-
guchi, 2005; Fontenot and Rudensky, 2005). However, 
thymic Treg development is dependent upon CD28 sig-
nals (Salomon et al., 2000; Tai et al., 2005) and, likely, on 
additional unknown and known factors such as STAT5 
activation downstream of γc cytokine receptors (Figure 
2; Fontenot et al., 2005a). Therefore, AP-1 and FOXP3 
are probably coexpressed in regulatory T cells develop-
ing in the thymus, implying a more complicated scenario 
depending upon relative concentrations of NFAT, AP-1, 
and FOXP3 as well as other yet unidentified FOXP3 tran-
scriptional partners and cofactors. Future dissection of 
temporal expression of these transcriptional regulators 
and their targets during thymic development of Treg 
cells and of signaling events affecting their expression 
will help to better understand the key mechanisms of 
recessive and dominant immunological tolerance.256 Cell 126, July 28, 2006 ©2006 Elsevier Inc.ACkNOwledgmeNTs
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